Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9022765 | 0.85 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL11467643 | 0.83 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL7815717 | 0.82 | OPRL1 (0.68) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL10060840 | 0.82 | OPRL1 (0.68) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL21523784 | 0.79 | CYP2D6 (0.41) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL11368796 | 0.79 | GRIN2B (0.46) | OPRL1OPRM1OPRK1OPRD1GRIN2B | |
| SCHEMBL1724862 | 0.78 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL19458977 | 0.78 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL28524217 | 0.78 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL1109741 | 0.78 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260118308-A1 | Rapid Point-of-Site Multiplexed Detection of Salivary Micro RNA in Mild TBI using Amplification-free Electrochemical Test | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2026-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260118308-A1 | Rapid Point-of-Site Multiplexed Detection of Salivary Micro RNA in Mild TBI using Amplification-free Electrochemical Test | METTL16, PYGB, EFTUD2 | OPRL1 3183/4885OPRM1 2334/4885OPRK1 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.